Association Between the Extent of Periodontal Inflammation and the Severity of Rheumatoid Arthritis in Japanese Patients With Rheumatoid Arthritis

Hiroko Hashimoto a, Shimpei Hashimoto b, Yoshihiro Shimazaki a*

a Department of Preventive Dentistry and Dental Public Health, School of Dentistry, Aichi Gakuin University, Nagoya, Japan
b Hashimoto Orthopaedic Surgery Clinic, Nagoya, Japan

ARTICLE INFO
Article history: Available online 17 March 2021
Key words: Periodontal inflammation Rheumatoid arthritis (RA) Biological therapy Epidemiology

ABSTRACT
Objective: Periodontal inflammation can affect the progression of rheumatoid arthritis (RA), and RA drugs may influence the periodontal condition of patients with RA. We examined whether the association between periodontal inflammation and the severity of RA is influenced by RA medication.

Methods: This cross-sectional study recruited 98 Japanese patients with RA from an orthopaedic clinic. We assessed the severity of RA using the Steinbrocker class and stage. The periodontal inflamed surface area (PISA) was used as an indicator of periodontal status. We obtained data on RA medications from medical records. We examined the associations among periodontal tissue inflammation, RA medications, and RA severity using multinomial logistic regression analyses.

Results: In univariate multinomial logistic regression analyses, no significant association between PISA score and RA severity was observed. There was no significant association between PISA score and RA severity in multivariate analyses not including variables about RA drugs as independent variables. However, in multivariate analyses adjusted for RA drugs and other confounding variables, patients with a PISA > 550 mm² had significantly higher odds ratios (ORs) for Steinbrocker class III-IV and stage III-IV (OR, 20.24; 95% confidence interval [CI], 1.78-229.85 and OR, 12.42; 95% CI, 1.79-86.49, respectively) compared to patients with PISA score ≤ 550 mm².

Conclusion: The extent of periodontal inflammation is associated with the severity of RA independent of RA medications.

© 2020 The Authors. Published by Elsevier Inc. on behalf of FDI World Dental Federation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Introduction
Rheumatoid arthritis (RA) is an autoimmune disease characterised by joint swelling and pain. 1 In Japan, about 1 million people (approximately 1.0% of the population) suffer from RA. 2 Periodontitis is a prevalent chronic inflammatory disease of periodontal tissue that increases the risk of tooth loss 3 and has been reported to be related to various systemic diseases, including diabetes, cardiovascular disease, and stroke. 4-6 Periodontitis is related to the onset and progression of RA. 7 Patients with RA and periodontitis had greater RA disease activity than those without periodontitis. 8 Among patients with arthralgia but not RA, those with periodontitis had a higher risk of developing RA than those without periodontitis. 9 Thus, inflammation of periodontal tissue may affect the onset and progression of RA. Studies of the relationship between RA and periodontitis have used various measures to evaluate the condition of the periodontal tissue, such as the periodontitis scale of the Centers for Disease Control and Prevention (CDC) and the American Academy of Periodontology (AAP), 10 the number of sites with a probing pocket depth (PPD) ≥ 4 mm, and the clinical attachment level (CAL) ≥ 4 mm. 11

* Corresponding author. Department of Preventive Dentistry and Dental Public Health, School of Dentistry, Aichi Gakuin University, 1-100 Kusumoto-cho, Chikusa-ku, Nagoya 464-8650, Japan.
E-mail address: shima@dpc.agu.ac.jp (Y. Shimazaki).
https://doi.org/10.1016/j.identj.2020.12.015
0020-6539/© 2020 The Authors. Published by Elsevier Inc. on behalf of FDI World Dental Federation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Given that periodontitis is a type of inflammation affecting periodontal tissue, local periodontal inflammation might influence RA. Thus, the relationship between the degree of periodontal tissue inflammation and RA must be investigated. The periodontal inflamed surface area (PISA) is used to evaluate the extent of local periodontal inflammation. Investigation of the relationship between the PISA score and severity of RA will provide insight into the relationship between periodontitis and RA.

Most patients with RA take 1 or more RA medications to prevent disease progression and achieve remission of symptoms. Typical RA medications include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), methotrexate (MTX), and biologic disease-modifying antirheumatic drugs (生物DMARDs). The periodontal condition of patients with RA improved after taking bDMARDs, suggesting that RA drugs may influence the periodontal condition of patients with RA. However, little information is available about the effects of periodontal inflammation and RA medication on the severity of RA.

This study was performed to investigate the relationship between periodontal inflammation assessed by the PISA score and the severity of RA in Japanese adults. In addition, we investigated the impact of RA medications on the association between the PISA score and the severity of RA.

Methods

Study population

This cross-sectional study examined different themes pertaining to patients we previously reported on; the methods for evaluating RA and oral health are based on that study. The diagnosis of RA was made by a rheumatologist in a private orthopaedic clinic based on the 1987 revised criteria of the American Rheumatism Association: (1) morning stiffness in and around joints lasting for ≥1 h before maximal improvement; (2) soft tissue swelling of 3 or more joint areas; (3) swelling of the proximal interphalangeal, metacarpophalangeal, or wrist joints; (4) symmetric swelling; (5) rheumatoid nodules; (6) radiographic evidence of erosion or periarticular osteopenia in the hand or wrist joints.

Criteria 1-4 must have been present for ≥6 weeks to be eligible for inclusion. RA was defined as the presence of 4 or more criteria. This study included only patients aged ≥18 years. Edentulous and pregnant patients were excluded. This study was approved by the Ethics Committee of the School of Dentistry of Aichi Gakuin University (approval number 405) and conducted in full accordance with the Declaration of Helsinki. All of the patients provided written informed consent. A total of 98 Japanese adults with RA (mean age, 62.7 ± 14.3 years) were recruited from an orthopaedic clinic in Aichi Prefecture, Japan between April 2015 and March 2016.

Assessment of clinical rheumatological parameters

The methods for assessing RA were based on our previous paper. The Steinbrocker functional classification was applied by a single dentist at the orthopaedic clinic using a portable chair under adequate artificial light; the dentist was blinded to the subjects’ rheumatoid data. The number of teeth was counted. As parameters of periodontal health status, PPD and bleeding on probing (BOP) were assessed at 6 points (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) around all teeth using a periodontal probe (CPUNC 15; Hu-Friedy). PPD was recorded to the nearest millimetre, and every observation close to 0.5 mm was rounded to the lowest whole number. BOP was distinguished dichotomously as the presence or absence of bleeding at 30 seconds after probing. Periodontal examiner reliability was verified by the intraexaminer calibration of 4 volunteers; the percentage of agreement (± 1 mm) for PPD ranged from 81.0% to 98.8%, and the χ² value ranged from 0.69 to 0.98. PISA, calculated as the sum of the PPD of BOP-positive sites in the total dentition, can be calculated from the periodontal chart. This method quantifies the surface area (mm²) of inflamed periodontal tissue as an indicator of the inflammatory and infectious burden of periodontitis. Also, it can be used to distinguish subjects with actively inflamed from those with noninflamed or healthy periodontal tissues. The PISA score was calculated after the PPD data and the incidence of BOP were entered into the PISA spreadsheet, which is publicly available at www.parsprototo.info.

Oral examination

The methods used for evaluating oral health were based on our previous paper. Patients’ oral health status was examined by a single dentist at the orthopaedic clinic using a portable chair under adequate artificial light; the dentist was blinded to the subjects’ rheumatoid data. The number of teeth was counted. As parameters of periodontal health status, PPD and bleeding on probing (BOP) were assessed at 6 points (mesiobuccal, midbuccal, distobuccal, mesiolingual, midlingual, and distolingual) around all teeth using a periodontal probe (CPUNC 15; Hu-Friedy). PPD was recorded to the nearest millimetre, and every observation close to 0.5 mm was rounded to the lowest whole number. BOP was distinguished dichotomously as the presence or absence of bleeding at 30 seconds after probing. Periodontal examiner reliability was verified by the intraexaminer calibration of 4 volunteers; the percentage of agreement (± 1 mm) for PPD ranged from 81.0% to 98.8%, and the χ² value ranged from 0.69 to 0.98. PISA, calculated as the sum of the PPD of BOP-positive sites in the total dentition, can be calculated from the periodontal chart. This method quantifies the surface area (mm²) of inflamed periodontal tissue as an indicator of the inflammatory and infectious burden of periodontitis. Also, it can be used to distinguish subjects with actively inflamed from those with noninflamed or healthy periodontal tissues. The PISA score was calculated after the PPD data and the incidence of BOP were entered into the PISA spreadsheet, which is publicly available at www.parsprototo.info.
Questionnaires

Height, body weight, and lifestyle factors were evaluated using a self-administered questionnaire. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of the height in meters. Smoking status was classified as never, former, or current smoker. A former smoker was defined as a patient who had smoked before but who did not smoke at the time of the investigation.

Statistical analyses

Each of the 2 RA evaluation indices was divided into 3 subcategories: class (I, II, and III-IV) and stage (I, II, and III-IV). RA drug type was classified into 2 categories: bDMARDs and other. The PISA score was divided at the 20th percentile (≤550 and >550 mm²), where this cutoff value has been used in a previous study. 19 The Mann–Whitney U-test and χ² test were used to analyse the relationships between PISA score and other variables. The Kruskal–Wallis and χ² tests were used to analyse the relationships between RA severity and other variables. Multinomial logistic regression analyses were performed to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the effects of PISA score and other variables on RA severity (class or stage). Age, sex, BMI, smoking status, number of teeth, PISA score, duration of RA treatments, duration of current RA drug use, and type of RA drug were included as independent variables in univariate and multivariate multinomial logistic regression analyses. In the multivariate analyses, we used 2 models. Model 1 included all independent variables of interest except duration of current RA drug use and type of RA drug, and model 2 included variables about RA drugs as independent variables. In all analyses, P < .05 was taken to indicate statistical significance. The statistical analyses were performed using SPSS version 23.0 software (IBM).

Results

Table 1 shows the characteristics of the RA patients and the relationships between the PISA score and other variables. Patients with PISA score >550 mm² had significantly higher PPD and BOP values than those with PISA score ≤550 mm². No significant relationships between PISA score and other variables in RA patients were observed.

Table 2 shows the relationships between RA severity (class, stage) and other variables in patients with RA. The patients in a higher class were significantly older, had fewer teeth, higher BOP value, longer duration of RA treatment, and higher rates of bDMARD use. The patients in a higher stage had a longer duration of RA treatment, longer duration of current RA drug use, higher rates of bDMARD use, and longer duration of DMARDs, corticosteroids, NSAIDs, and MTX use.

Table 3 shows the results of univariate and multivariate multinomial logistic regression analyses of the effects of PISA score and other variables on RA severity (class). Older patients had significantly higher ORs for class II and class III-IV in multivariate analyses. Compared to the patients with PISA ≤550 mm², those with PISA score >550 mm² had significantly higher ORs for class III-IV in model 2 (OR, 20.24; 95% CI, 1.78-229.85).

Table 4 shows the results of univariate and multivariate multinomial logistic regression analyses of the effect of PISA score and other variables on RA severity (stage). In model 1, patients with a longer duration of RA treatment had significantly higher ORs for stage III-IV. In model 2, patients with PISA score >550 mm² had a significantly higher OR (12.42; 95% CI, 1.79-86.49) for stage III-IV compared to patients with PISA score ≤550 mm². Patients taking bDMARDs had a significantly higher OR for stage III-IV in model 2.

Discussion

The RA patients who had severe periodontal tissue inflammation, as evaluated by the PISA score, had more severe RA, suggesting that periodontal tissue inflammation is linked to RA severity.

A previous study indicated that the prevalence of RA was higher in patients with periodontitis compared to those without periodontitis. 20 A study following patients with arthritis but not RA for 2 years indicated that those with periodontal pockets ≥4 mm had a significantly higher risk of developing RA. 21 Patients with RA and periodontitis had greater RA disease activity than those without periodontitis. 22 In this study, patients with RA and severe periodontal inflammation had more severe RA. Because periodontal tissue inflammation may affect RA severity by causing citrullination, 23,24 it might be important for patients with RA to visit a dental clinic and receive appropriate periodontal treatment to reduce periodontal inflammation to prevent worsening of RA.

The patients with RA and periodontitis had more severe joint destruction, as determined by radioscopy, and a higher disease activity score (based on the level of C-reactive protein [DAS 28-CRP]) than do patients with RA without periodontitis. 19 However, other studies have found no significant association between periodontal status and RA severity. 25-27 Most of those studies did not consider the effects of RA drugs on the association between periodontitis and the severity of RA. In this study, there was no significant association between periodontal inflammation and RA severity in the crude analysis, but their association was enhanced after adjustment for confounders. Furthermore, in multivariate analyses including variables pertaining to RA drugs, the strongest association was found between the PISA score and RA severity. RA medications may play an important role in the relationship between periodontal tissue inflammation and the severity of RA.

In a study of the associations among periodontal status, RA severity, and RA medication, patients with RA taking an interleukin-6 (IL-6) inhibitor showed decreased matrix metalloproteinase-3 (MMP-3; a serum marker of joint destruction), gingivitis index, BOP, and PPD compared to those not taking the drug. 14 Also, in a study in which patients with RA were given tumour necrosis factor-α (TNF-α) inhibitors, the DAS 28-CRP level, gingival index, BOP, and PPD decreased. 28 IL-6 and TNF-α are important inflammatory cytokines related to both RA and periodontitis, 29 and their inhibition by bDMARDs would ameliorate both RA and periodontitis. 30,31,32
In this study, the type of RA drug was significantly associated with the severity of RA, and patients with severe RA had a higher rate of taking bDMARDs. Our results were expected because the subjects in this study had taken RA drugs, and patients with severe RA were more frequently bDMARD users. By contrast, bDMARDs were reported to improve not only the symptoms of RA but also inflammation of periodontal tissue.14,15 In this study, although there was no significant relationship between PISA score and the duration of bDMARD use, patients with lower PISA score had been taking bDMARDs for longer. Therefore, it is possible that bDMARDs ameliorated periodontal tissue inflammation in the patients with RA, and the real impact of periodontal inflammation on the severity of RA may have been underestimated in this study. In fact, in a multivariate analysis, the strength of the association between the PISA score and the severity of RA increased after adjustment for RA medications, suggesting that severe inflammation of periodontal tissue may increase the severity of RA in patients not taking bDMARDs. Therefore, the influence of periodontal tissue inflammation on the severity of RA was demonstrated by adjusting for the influence of RA drugs in the multivariate analysis. In future studies, RA drugs should be included in evaluations of the effects of periodontal disease on RA severity.

Although bDMARDs have been reported to improve not only the symptoms of RA but also inflammation of periodontal tissue and periodontal pockets,14 in a cross-sectional study, there were no significant differences in the PPD or CAL between bDMARD users and antirheumatic drugs users.27 However bDMARD users had higher levels of gum inflammation as assessed by BOP and the papilla bleeding index.27 In addition, another study showed that attachment loss decreased after patients took bDMARDs, but the gingivitis index increased.28 Because bDMARDs suppress bone

---

Table 1 – Relationships between the PISA score and other variables in patients with RA.

|                      | Total RA patients (N = 98) | PISA score (mm²) |  
|----------------------|---------------------------|------------------|---
|                      |                           | ≤550 (n = 78)    | > 550 (n = 20) | P value* |
| Age                  | 62.5 (54.0, 74.0)         | 62.0 (51.8, 75.0) | 65.5 (57.0, 71.0) | .55 |
| Sex                  |                           |                  |                |        |
| Male                 | 29 (29.6)                 | 22 (28.2)        | 7 (35.0)       | .55 |
| Female               | 69 (70.4)                 | 56 (71.8)        | 13 (65.0)      |       |
| BMI (kg/m²)          | 21.3 (19.3, 23.5)         | 21.6 (19.6, 23.5) | 19.3 (18.4, 23.0) | .06 |
| Smoking status       |                           |                  |                |        |
| Never smoker         | 54 (55.1)                 | 45 (57.7)        | 9 (45.0)       | .38 |
| Former smoker        | 21 (21.4)                 | 17 (21.8)        | 4 (20.0)       |       |
| Current smoker       | 23 (23.4)                 | 16 (20.5)        | 7 (35.0)       |       |
| Number of teeth      | 24.0 (16.8, 27.3)         | 24.0 (15.3, 28.0) | 24.0 (19.0, 26.8) | .81 |
| Mean PPD (mm)        | 2.85 (2.53, 3.30)         | 2.69 (2.50, 3.01) | 3.38 (3.01, 3.86) | <.001 |
| Mean BOP (%)         | 20.3 (9.97, 41.7)         | 16.1 (7.79, 27.1) | 43.4 (35.9, 69.8) | <.001 |
| PPD (mm)             |                           |                  |                |        |
| ≤3                   | 3 (3.1)                   | 3 (3.8)          | 0 (0.0)        | <.001 |
| > 4-5                | 52 (53.1)                 | 47 (60.3)        | 5 (25.0)       |       |
| ≥6                   | 43 (43.9)                 | 28 (35.9)        | 15 (75.0)      |       |
| BOP (%)              |                           |                  |                |        |
| <10                  | 24 (24.5)                 | 24 (30.8)        | 0 (0.0)        | <.001 |
| 10-29.9              | 38 (38.8)                 | 37 (47.4)        | 1 (5.0)        |       |
| ≥30                  | 36 (36.7)                 | 17 (21.8)        | 19 (95.0)      |       |
| RA severity (Class)  |                           |                  |                |        |
| I                    | 68 (69.4)                 | 57 (73.1)        | 11 (55.0)      | .29 |
| II                   | 17 (17.3)                 | 12 (15.4)        | 5 (25.0)       |       |
| III-IV               | 13 (13.3)                 | 9 (11.5)         | 4 (20.0)       |       |
| RA severity (Stage)  |                           |                  |                |        |
| I                    | 60 (61.2)                 | 49 (62.8)        | 11 (55.0)      | .39 |
| II                   | 19 (19.4)                 | 16 (20.5)        | 3 (15.0)       |       |
| III-IV               | 19 (19.4)                 | 13 (16.7)        | 6 (30.0)       |       |
| Duration of RA treatment (month) | 25.5 (4.0, 74.5) | 27.5 (3.75, 76.0) | 21.5 (9.0, 62.2) | .49 |
| Duration of current RA drug use (month) | 12.0 (2.0, 34.8) | 13.0 (2.0, 37.5) | 10.0 (2.0, 17.0) | .13 |
| Type of RA drug      |                           |                  |                |        |
| DMARDs/Corticosteroids/NSAIDs/MTX | 74 (75.5) | 57 (73.1) | 17 (85.0) | .21 |
| bDMARDs              | 24 (24.5)                 | 21 (26.9)        | 3 (15.0)       |       |
| Duration of DMARDs/Corticosteroids/NSAIDs/MTX use (month) (n = 74) | 6.5 (2.0, 18.8) | 6.5 (2.0, 25.5) | 6.5 (1.3, 15.8) | .40 |
| Duration of bDMARDs use (month) (n = 24) | 36.0 (12.0, 66.0) | 36.0 (15.0, 66.0) | 21.0 (2.0, 36.0) | .26 |

bDMARDs, biologic disease-modifying antirheumatic drugs; BMI, body mass index; BOP, bleeding on probing; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; PISA, periodontal inflamed surface area; PPD, probing pocket depth; RA, rheumatoid arthritis.

Data are presented as median (25 percentile, 75 percentile) or number with percentages given in parentheses.

* Differences among groups, analysed using Mann-Whitney U test or χ² test.
| RA severity (Class) | RA severity (Stage) |
|---------------------|---------------------|
| I (n = 68)          | II (n = 17)         | III-IV (n = 13) | P value* | I (n = 70)          | II (n = 19) | III-IV (n = 19) | P value* |
| Age                 | 59.5 (50.0, 66.8) | 68.0 (58.0, 78.0) | 79.0 (72.0, 85.5) | <.001 | 62.0 (54.0, 71.8) | 65.0 (55.0, 81.0) | 65.0 (50.0, 79.0) | .58 |
| Sex                 | Male 23 (33.8) | 5 (29.4) | 1 (7.6) | .17 | 21 (35.0) | 5 (26.3) | 3 (15.8) | .26 |
|                    | Female 45 (66.2) | 12 (70.5) | 12 (92.3) | 39 (65.0) | 14 (73.7) | 16 (84.2) | |
| BMI (kg/m²)         | 21.7 (19.2, 23.5) | 20.5 (19.6, 22.8) | 19.9 (17.8, 22.8) | .50 | 21.3 (19.2, 23.5) | 21.4 (19.5, 27.3) | 20.0 (19.1, 23.1) | .63 |
| Smoking status      | Never smoker 31 (45.6) | 13 (76.5) | 10 (76.9) | .05 | 29 (48.3) | 10 (52.6) | 15 (78.9) | .23 |
|                    | Former smoker 16 (23.5) | 3 (17.6) | 2 (15.4) | 15 (25.0) | 4 (21.1) | 2 (10.5) | |
|                    | Current smoker 21 (30.9) | 1 (5.9) | 1 (7.7) | 16 (36.7) | 5 (26.3) | 2 (10.5) | |
| Number of teeth     | 25.5 (20.0, 28.0) | 23.0 (18.0, 26.0) | 12.0 (7.5, 25.0) | .01 | 24.5 (18.0, 27.0) | 23.0 (16.0, 28.0) | 24.0 (11.0, 27.0) | .93 |
| Mean PPD (mm)       | 2.75 (2.52, 3.19) | 2.84 (2.45, 3.17) | 3.07 (2.83, 4.4) | .06 | 2.79 (2.54, 3.32) | 2.88 (2.52, 3.02) | 2.90 (2.52, 3.78) | .63 |
| Mean BOP (%)        | 18.1 (8.90, 36.0) | 14.8 (10.6, 33.3) | 44.9 (18.6, 69.0) | .03 | 20.4 (8.90, 41.3) | 18.3 (12.7, 40.7) | 21.7 (14.8, 61.1) | .62 |
| PISA score (mm²)    | ≤550 57 (83.8) | 12 (70.6) | 9 (69.2) | .29 | 49 (81.7) | 16 (74.2) | 13 (68.4) | .39 |
|                    | >550 11 (16.2) | 5 (29.4) | 4 (30.8) | 11 (18.3) | 5 (15.8) | 6 (31.6) | |
| Duration of RA treatment (month) | 18.0 (3.0, 62.3) | 53.0 (15.0, 82.5) | 49.0 (24.5, 88.0) | .03 | 15.5 (2.0, 45.3) | 66.0 (4.0, 81.0) | 86.0 (26.0,96.0) | <.001 |
| Duration of current RA drug use (month) | 8 (2.0, 27.0) | 17.0 (2.25, 48.0) | 24.0 (7.0, 62.0) | .15 | 6.0 (2.0,19.0) | 24.0 (4.0, 66.0) | 23.5 (9.75, 66.2) | <.001 |
| Type of RA drug     | DMARDs/Corticosteroids/NSAIDs/MTX 60 (88.2) | 10 (58.8) | 4 (30.8) | .<.001 | 54 (90.0) | 13 (68.4) | 7 (36.8) | <.001 |
|                    | bDMARDs 8 (11.8) | 7 (41.2) | 9 (69.2) | 6 (10.0) | 6 (31.6) | 12 (63.2) | |
| Duration of bDMARDs/Corticosteroids/NSAIDs/MTX use (month) (n = 74) | 6.0 (2.0, 18.0) | 4.0 (1.5, 20.5) | 21.0 (13.0, 51.5) | .19 | 4.0 (2.0, 16.5) | 14.0 (4.0, 69.0) | 16.5 (9.75, 34.5) | .02 |
| Duration of bDMARDs use (month) (n = 24) | 33.5 (15.0, 66.0) | 49.0 (17.0, 68.0) | 24.0 (2.0, 73.0) | .78 | 26.0 (12.7, 36.0) | 58.0 (18.3, 66.5) | 42.5 (5.7, 70.7) | .46 |

bDMARDs, biologic disease-modifying antirheumatic drugs; BMI, body mass index; BOP, bleeding on probing; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; PISA, periodontal inflamed surface area; PPD, probing pocket depth; RA, rheumatoid arthritis.

Data are presented as median (25 percentile, 75 percentile) or number with percentages giving in parentheses.

* Differences among groups, analysed using Kruskal-Wallis test or x² test.
Table 3 – Associations of periodontal status and other variables with the severity of RA (class) by univariate and multivariate multinomial logistic regression analyses.

| Independent variable | Model 1 |          | Model 2 |          |
|----------------------|---------|----------|---------|----------|
|                      | II vs I | III-IV vs I | II vs I | III-IV vs I |
|                      | Crude OR (95% CI) | Adjusted OR (95% CI) | Crude OR (95% CI) | Adjusted OR (95% CI) |
| Age                  | 1.07 (1.02, 1.12) * | 1.08 (1.01, 1.15) * | 1.10 (1.02, 1.18) * |
| Sex                  | 1.23 (0.39, 3.91) | 0.57 (0.11, 2.91) | 0.51 (0.09, 2.88) |
| Male                 | 1.08 (0.75, 1.15) | 0.93 (0.72, 1.20) | 0.92 (0.73, 1.17) |
| Female               | 1.17 (1.08, 1.26) | 1.18 (1.06, 1.32) | 1.19 (1.05, 1.34) |
| Smoking status       | 0.95 (0.82, 1.11) | 0.93 (0.76, 1.15) | 0.92 (0.73, 1.17) |
| Never smoker         | 1        | 1        | 1        |
| Current smoker       | 0.39 (0.08, 1.99) | 0.62 (0.07, 5.50) | 0.60 (0.05, 6.98) |
| Male                 | 0.38 (0.07, 2.05) | 0.57 (0.02, 14.78) | 0.72 (0.02, 30.13) |
| Female               | 0.15 (0.01, 1.24) | 0.13 (0.01, 1.87) | 0.13 (0.01, 1.87) |
| Number of teeth      | 0.99 (0.92, 1.06) | 1.02 (0.93, 1.12) | 1.03 (0.93, 1.14) |
| PISA score (mm²)     | 0.89 (0.83, 0.96) | 0.93 (0.83, 1.04) | 0.94 (0.82, 1.06) |
| ≤550                 | 1        | 1        | 1        |
| >550                 | 2.16 (0.63, 7.36) | 2.11 (0.46, 9.61) | 2.11 (0.46, 9.61) |
| Duration of RA treatment (month) | 1.01 (1.00, 1.02) | 1.01 (1.00, 1.02) | 1.01 (1.00, 1.02) |
| Current RA drug use (month) | 1.01 (0.99, 1.03) | 1.02 (1.00, 1.04) | 1.02 (0.98, 1.05) |
| Type of RA drug      |          |          |          |
| DMARDs/Corticosteroids/NSAIDs/MTX | 1 | 1 | 1 |
| bDMARDs              | 5.25 (1.56, 17.70) | 6.89 (4.20, 67.73) | 4.31 (0.74, 25.14) |

bDMARDs, biologic disease-modifying antirheumatic drugs; BMI, body mass index; CI, confidence interval; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PISA, periodontal inflamed surface area; RA, rheumatoid arthritis.

Model 1 used age, sex, BMI, smoking status, number of teeth, PISA score, and duration of RA treatment as independent variables. Model 2 used age, sex, BMI, smoking status, number of teeth, PISA score, duration of RA treatment, duration of current RA drug use, and type of RA drug as independent variables.

* P < .05.
† P < .01.
### Table 4 – Associations of periodontal status and other variables with the severity of RA (stage) by univariate and multivariate multinomial logistic regression analyses.

| Independent variable | Model 1 (Dependent variable: Stage II vs I) | Model 1 (Dependent variable: Stage III-IV vs I) | Model 2 (Dependent variable: Stage II vs I) | Model 2 (Dependent variable: Stage III-IV vs I) |
|----------------------|---------------------------------------------|-----------------------------------------------|---------------------------------------------|-----------------------------------------------|
|                      | Crude OR (95% CI)                           | Adjusted OR (95% CI)                          | Crude OR (95% CI)                           | Adjusted OR (95% CI)                          |
| Age                  | 1.01 (0.98, 1.05)                           | 1.02 (0.98, 1.07)                             | 0.99 (0.94, 1.05)                           | 1.02 (0.97, 1.08)                             |
| Sex                  |                                             |                                               |                                             |                                               |
| Male                 | 1                                           | 1                                             | 1                                           | 1                                             |
| Female               | 1.51 (0.48, 4.77)                           | 1.84 (0.45, 7.43)                             | 1.35 (0.25, 7.24)                           | 1.69 (0.36, 7.92)                             |
| BMI (kg/m²)          | 1.10 (0.97, 1.26)                           | 1.11 (0.95, 1.29)                             | 1.07 (0.90, 1.28)                           | 1.12 (0.94, 1.34)                             |
| Smoking status       |                                             |                                               |                                             |                                               |
| Never smoker         | 1                                           | 1                                             | 1                                           | 1                                             |
| Former smoker        | 0.77 (0.21, 2.89)                           | 0.83 (0.18, 3.71)                             | 0.25 (0.04, 1.52)                           | 0.74 (0.15, 3.68)                             |
| Current smoker       | 0.91 (0.26, 3.12)                           | 1.12 (0.25, 5.10)                             | 0.12 (0.01, 1.09)                           | 1.05 (0.20, 5.53)                             |
| Number of teeth      | 0.99 (0.93, 1.06)                           | 1.02 (0.94, 1.12)                             | 0.96 (0.87, 1.06)                           | 1.03 (0.93, 1.13)                             |
| PISA score (mm²)     |                                             |                                               |                                             |                                               |
| ≤550                 | 1                                           | 1                                             | 1                                           | 1                                             |
| >550                 | 0.84 (0.21, 3.37)                           | 1.02 (0.22, 4.66)                             | 3.43 (0.77, 15.3)                           | 1.84 (0.35, 9.62)                             |
| Duration of RA treatment (month) | 1.01 (1.00, 1.03)* | 1.01 (1.00, 1.03) | 1.01 (1.00, 1.03) | 1.01 (1.00, 1.03) |
| Duration of current RA drug use (month) | 1.04 (1.02, 1.07) | 1.04 (1.02, 1.07) | 1.04 (1.02, 1.07) | 1.04 (1.02, 1.07) |
| Type of RA drug      |                                             |                                               |                                             |                                               |
| DMARDs/Corticosteroids/NSAIDs/MTX | 1 | 1 | 1 | 1 |
| bDMARDs              | 4.15 (1.15, 14.99)*                          | 15.43 (4.39, 54.23)*                          | 2.08 (0.39, 11.14)                          | 9.10 (1.48, 55.82)*                          |

bDMARDs, biologic disease-modifying antirheumatic drugs; BMI, body mass index; CI, confidence interval; DMARDs, disease-modifying antirheumatic drugs; MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PISA, periodontal inflamed surface area; RA, rheumatoid arthritis.

Model 1 used age, sex, BMI, smoking status, number of teeth, PISA score, and duration of RA treatment as independent variables. Model 2 used age, sex, BMI, smoking status, number of teeth, PISA score, duration of RA treatment, duration of current RA drug use, and type of RA drug as independent variables.

* P < .05.

\( P < .01. \)
In this study, we used class classification of functional disability and stage classification of joint destruction based on X-ray findings to categorise RA severity, and the PISA score was more strongly associated with the class classification. This suggests that periodontal tissue inflammation is more strongly associated with dysfunction than the morphological findings in patients with RA. Because bDMARDs suppress bone destruction, they are used for many patients with a high stage classification, and the type of RA medication may affect the association between periodontal tissue inflammation and RA severity. The RA medication is selected based on disease severity and activity. In this study, when the use of MTX did not improve severe RA, physicians often used a bDMARD to avoid a decline in activities of daily living and progression of disease. In fact, many of the patients taking bDMARDs had severe RA. We considered the duration of RA treatment and current RA drug use. However, we were not able to examine the changes of RA medications or combination drug treatments. Further studies should obtain more information to better understand the impact of RA drugs on the association between periodontitis and RA severity.

In this study, we examined the effect of periodontal tissue inflammation on RA severity. Many studies have shown that RA severity is associated with periodontitis, patients with RA had more severe gingival inflammation and chronic periodontal destruction compared to controls matched for age, sex, smoking status, and oral hygiene status. Therefore, a reciprocal relationship may exist between these 2 variables. Although cross-sectional studies cannot indicate the direction of an association, it is important to note the 2-way relationship between these 2 variables.

Smoking is a risk factor for RA, and the incidence of RA has been reported to be higher in smokers than in nonsmokers. However, in this study, the percentage of smokers was higher among patients with lower RA severity. All participants in this study were patients with RA; we did not perform comparisons between non-RA and RA subjects. Therefore, it is possible that there is no statistically significant relationship between RA severity and smoking status.

This study had several limitations. Because this was a cross-sectional study, it was impossible to infer causality regarding the association between periodontitis and RA severity. As this study involved a small group of patients who visited a particular orthopaedic clinic, the distribution of RA severity may differ from that in the general population. Because the number of participants in this study was small, the changes in OR in each analysis were large, and the CIs were relatively wide. To obtain more reliable results, more patients should be analysed. In addition, this study enrolled patients who could attend a clinic, and it did not include those with severe RA who required hospitalisation. To clarify the association between RA and periodontal disease, a large-scale study of patients with RA of varying severity and using various medications is needed. We did not consider the dose of medication, the use of multiple medications in each patient, or changes in medication during the course of treatment. In addition, the effects of environmental factors related to RA, such as viral infection, diet, and hormones, were not considered. Future studies should consider other environmental factors that aggravate RA.

Conclusion

Patients with RA who had a high PISA score (indicating inflammation of periodontal tissue) were more likely to have severe RA; thus, inflammation of periodontal tissue in patients with RA may affect RA symptoms. Also, the relationship increased when RA drug type and duration of current RA drug use was considered, suggesting that RA drugs should be included in analyses of the relationship between periodontal tissue inflammation and the severity of RA. It is important to reduce inflammation of periodontal tissue in patients with RA by improving their oral hygiene and providing appropriate periodontal treatment. Further prospective studies are needed to understand how periodontal inflammation affects the severity of RA.

Conflict of interest

None disclosed.

Acknowledgements

The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/FqvP3r

Funding

The present study was supported by a Grant-in-Aid for Scientific Research (no. 16K11875) from Japan Society for the Promotion of Science, Tokyo, Japan, and by the department budget of Aichi Gakuin University.

REFERENCES

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903–11.
2. Yamanaka H, Sugiyama N, Inoue E, Taniguchi A, Momohara S. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (J). Mod Rheumatol 2014;24:33–40.
3. Page RC, Offenbacher S, Schroeder HE, Seymour GJ, Kornman KS. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000 1999;14:216–48.

4. Iacopino AM, Cutler CW. Pathophysiological relationships between periodontitis and systemic disease: recent concepts involving serum lipids. J Periodontol 2000;71:1375–84.

5. Persson GR, Persson RE. Cardiovascular disease and periodontitis: an update on the associations and risk. J Clin Periodontol 2008;35:362–79.

6. Taylor JJ, Preshaw PM, Lalla E. A review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes. J Periodontol 2013;84:S113–34.

7. Paul BJ, Kandy HI, Krishnan V. Pre-rheumatoid arthritis and its prevention. Eur J Rheumatol 2017;4:161–5.

8. Mikuls TR, Payne JB, Yu F, et al. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:1090–100.

9. Hashimoto M, Yamazaki T, Hamaguchi M, et al. Periodontitis and Porphyromonas gingivalis in preclinical stage of arthritis patients. PLoS One 2015;10:e0122121.

10. Ayrväinen L, Leirisalo-Repo M, Kuuliala A, et al. Periodontitis in early and chronic rheumatoid arthritis: a prospective follow-up study in Finnish population. BMJ Open 2017;7:e011916.

11. Okada M, Kobayashi T, Ito S, et al. Periodontal treatment decreases levels of antibodies to Porphyromonas gingivalis and citrulline in patients with rheumatoid arthritis and periodontitis. J Periodontol 2013;84:e74–84.

12. Nesse W, Abbas F, van der Ploeg I, Spijkervet FK, Dijkstra PU, Vissink A. Periodontal inflamed surface area: quantifying inflammatory burden. J Clin Periodontol 2008;35:668–73.

13. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492–509.

14. Kobayashi T, Okada M, Ito S, et al. Assessment of interleukin-6 receptor inhibition therapy on periodontal condition in patients with rheumatoid arthritis and chronic periodontitis. J Periodontol 2014;85:57–67.

15. Kobayashi T, Yokoyama T, Ito S, et al. Periodontal and serum protein profiles in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitor adalimumab. J Periodontol 2014;85:1480–8.

16. Hashimoto H, Hashimoto S, Muto A, Dewake N, Shimazaki Y. Influence of plaque control on the relationship between rheumatoid arthritis and periodontal health status among Japanese rheumatoid arthritis patients. J Periodontol 2016;87:1033–42.

17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.

18. Steinbrocker O, Traeger CH, Batterner RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140:659–62.

19. Sakanoaka A, Kuboniwa M, Hashino E, Bamba T, Fukusaki E, Amano A. Distinct signatures of dental plaque metabolic byproducts dictated by periodontal inflammatory status. Sci Rep 2017;7:42818.

20. Mercado F, Marshall RI, Klestov AC, Bartold PM. Is there a relationship between rheumatoid arthritis and periodontal disease? J Clin Periodontol 2000;27:267–72.

21. Lee YH, Baharuddin NA, Chan SW, et al. Localisation of citrullinated and carbamylated proteins in inflamed gingival tissues from rheumatoid arthritis patients. Clin Oral Investig [Preprint]. Available from: https://link.springer.com/article/10.1007/s00784-020-03452-9. Accessed March 10, 2021.

22. Rahajoe PS, de Smit M, Schuurmans G, et al. Increased IgA anti-citrullinated protein antibodies in the periodontal inflammatory exudate of healthy individuals compared to rheumatoid arthritis patients. J Clin Periodontol 2020;47:552–60.

23. Mobini M, Maboudi A, Ali Mohammadpour R. Periodontitis in rheumatoid arthritis patients, abundance and association with disease activity. Med J Islam Repub Iran 2017;31:44.

24. Joseph R, Rajappan S, Nath SG, Paul BJ. Association between chronic periodontitis and rheumatoid arthritis: a hospital-based case-control study. Rheumatol Int 2013;33:103–9.

25. Khantisopon N, Louthrenoo W, Kasitanon N, et al. Periodontal disease in Thai patients with rheumatoid arthritis. Int J Rheum Dis 2014;17:511–8.

26. Kobayashi T, Yoshih H. Host responses in the link between periodontitis and rheumatoid arthritis. Curr Oral Health Rep 2015;2:1–8.

27. Ziebolz D, Rupprecht A, Schmickler J, et al. Association of different immunosuppressive medications with periodontal condition in patients with rheumatoid arthritis: results from a cross-sectional study. J Periodontal 2018;89:1310–7.

28. Pers JO, Saraux A, Pierre R, Youinou P. Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. J Periodontal 2008;79:1645–51.

29. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625–39.

30. Kasser UR, Gleissner C, Dehne F, Michel A, Willershuis-Zonnchen B, Bolten WW. Risk for periodontal disease in patients with longstanding rheumatoid arthritis. Arthritis Rheum 1997;40:2248–51.

31. Mercado FB, Marshall RI, Klestov AC, Bartold PM. Relationship between rheumatoid arthritis and periodontitis. J Periodontol 2001;72:779–87.

32. Pischon N, Pischon T, Kroger J, et al. Association among rheumatoid arthritis, oral hygiene, and periodontitis. J Periodontol 2008;79:979–86.

33. Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2010;69:70–81.